Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.56 |
| ▸ | CNR2 | P34972 | 14/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11542647 | 0.83 | CNR1 (0.60) | CNR1CNR2 | |
| SCHEMBL10365544 | 0.76 | CNR1 (0.57) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL11542888 | 0.76 | CNR1 (0.48) | CNR1CNR2 | |
| SCHEMBL11371918 | 0.72 | CNR2 (0.55) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL11734540 | 0.72 | CNR1 (0.46) | CNR1CNR2 | |
| SCHEMBL31545630 | 0.71 | CNR1 (0.84) | CNR1CNR2 | |
| SCHEMBL31545529 | 0.71 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL11603173 | 0.71 | CNR2 (0.53) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL11601989 | 0.71 | CNR2 (0.49) | CNR1CNR2NR1I2ADORA3SLC6A3 | |
| SCHEMBL11603359 | 0.71 | CNR2 (0.50) | CNR1CNR2NR1I2ADORA3SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197837-B2 | Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse | ACURA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11077196-B2 | Abuse-deterrent pharmaceutical composition | G.L. PHARMA GmbH (AT) | 2021-08-03 | — | — | US | disclosed |
| EP-3151819-B1 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | ACURA PHARMACEUTICALS INC (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200188334-A1 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | ACURA PHARMACEUTICALS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10610497-B2 | Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse | ACURA PHARMACEUTICALS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3560484-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2019-10-30 | — | — | EP | disclosed |
| EP-3423034-B1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G L PHARMA GMBH (AT) | 2019-07-10 | — | — | EP | disclosed |
| US-20180263933-A1 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | ACURA PHARMACEUTICALS, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| EP-3210596-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION | G.L. Pharma GmbH (AT) | 2017-08-30 | — | — | EP | disclosed |